These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11706990)

  • 1. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesylated proteins and cell cycle progression.
    Tamanoi F; Kato-Stankiewicz J; Jiang C; Machado I; Thapar N
    J Cell Biochem Suppl; 2001; Suppl 37():64-70. PubMed ID: 11842430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W; Lebowitz PF; Prendergast GC
    Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
    Sebti SM
    Cancer Cell; 2005 Apr; 7(4):297-300. PubMed ID: 15837619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
    Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting protein prenylation for cancer therapy.
    Berndt N; Hamilton AD; Sebti SM
    Nat Rev Cancer; 2011 Oct; 11(11):775-91. PubMed ID: 22020205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
    Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
    J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
    Prendergast GC
    Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
    Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
    Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
    J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.